12 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial (WAKE-UP)
Date du début: 1 déc. 2011, Date de fin: 30 nov. 2017,
WAKE-UP is an investigator-initiated, multicentre, randomised, double-blind, placebo-controlled trial designed to test efficacy and safety of MRI-based intravenous thrombolysis in patients with wake-up stroke. Every year 1.5 million patients suffer a stroke in the EU. Up to 20% of stroke patients wake up with stroke symptoms. Currently these patients are excluded from thrombolysis which is the onl ...
Voir le projet
13
Participants partenaires
TERMINÉ
Resistance in Gram-Negative Organisms: Studying Intervention Strategies (R-GNOSIS)
Date du début: 1 oct. 2011, Date de fin: 31 mars 2017,
Antibiotics are a mainstay of public health, but their use has increased exponentially leading to the emergence of antibiotic resistance. The R-GNOSIS (Resistance in Gram-Negative Organisms: Studying Intervention Strategies) project combines 5 international clinical studies, all supported by highly innovative microbiology, mathematical modelling and data-management, to determine - in the most rele ...
Voir le projet
27
Participants partenaires
TERMINÉ
Treatment of Adrenal Insufficiency in neonates- Development of a Hydrocortisone Preparation for the treatment of Adrenal Insufficiency in neonatesand infants (TAIN)
Date du début: 1 déc. 2011, Date de fin: 30 nov. 2016,
The aim of TAIN is to develop a neonatal formulation of hydrocortisone, a drug included in the EMA priority list that needs specific evaluation in the age range 0 – 2 years (neonates & infants). Hydrocortisone is an essential glucocorticoid hormone used as replacement therapy for the treatment of congenital and acquired adrenal insufficiency as well playing an important therapeutic role in oncolog ...
Voir le projet
8
Participants partenaires
TERMINÉ
Programming cellular networks and community behaviour with synthetic RNA-based devices (RiboNets)
Date du début: 1 sept. 2013, Date de fin: 31 août 2016,
RiboNets aims at programming cellular networks and community behaviour using newly engineered logical gates that transmit and process information within cells in an innovative way, namely via RNA-based devices.RiboNets wants to develop a newly designed RNA-based toolbox for cellular computing. RNA has three major advantages: (a) RNA turnover is fast thus efficient computing is possible with RNA ne ...
Voir le projet
4
Participants partenaires
TERMINÉ
The MEtabolic Road to DIAstolic Heart Failure (MEDIA)
Date du début: 1 janv. 2011, Date de fin: 30 juin 2016,
More than 50% of heart failure (HF) patients present without a major deficit of left ventricular (LV) systolic function and are presumed to suffer from diastolic HF (DHF) because diastolic LV distensibility is usually impaired in these patients. The vast majority (~80%) of DHF patients is exposed to metabolic risk factors. The MEDIA consortium therefore investigates:1) how metabolic derangements c ...
Voir le projet
23
Participants partenaires
TERMINÉ
Type 2 diabetes and obesity among sub-Saharan African native and migrant populations: dissection of environment and endogenous predisposition (RODAM)
Date du début: 1 janv. 2012, Date de fin: 30 sept. 2015,
"Migration from Sub-Saharan Africa (SSA) to Europe is increasing. The limited evidence suggests that the risk of type 2 diabetes (T2D) and obesity among SSA migrants is higher than among their SSA peers living in Africa and European host populations. The reasons for these observations are only poorly understood, but may involve migration-related changes in lifestyle, genetic predisposition as well ...
Voir le projet
9
Participants partenaires
TERMINÉ
New tools for monitoring drug resistance and treatment response in visceral leishmaniasis in the Indian subcontinent (KALADRUG-R)
Date du début: 1 nov. 2008, Date de fin: 30 avr. 2013,
"Visceral leishmaniasis (VL), one of the most-neglected infectious diseases, has an annual incidence of 500,000 cases. Early treatment is a major pillar of the current program for VL elimination on the Indian sub-continent. However, the arsenal of available drugs is very limited, and their use is jeopardized by drug resistance. Combination regimens for VL are under clinical development, but it wil ...
Voir le projet
10
Participants partenaires
TERMINÉ
Fighting Aneurysmal Diseases (FAD)
Date du début: 1 juil. 2008, Date de fin: 30 juin 2012,
"Fighting Aneurysmal Diseases (FAD) is a public health in EU, because of the ageing population. In the absence of intervention, aneurysms evolve towards rupture and death. The translational objectives of the project are to accelerate the acquisition of knowledge, and to develop new diagnostic and therapeutic tools for FAD in humans. The project innovates by integrating two different localizations ...
Voir le projet
15
Participants partenaires
TERMINÉ
European Network for the Study of Orphan Nephropathies (EUNEFRON)
Date du début: 1 mai 2008, Date de fin: 30 avr. 2012,
"In this proposal, we have mobilized a critical mass of expertise to investigate, on a Europe-wide scale, the natural history and pathophysiology of rare inherited diseases affecting important structures of the kidney. The project will use and develop multiple models (in vitro and in vivo) with the aim to develop preventive, diagnostic and therapeutic interventions that should alleviate the burden ...
Voir le projet
10
Participants partenaires
TERMINÉ
Mitochondrial dysfunction in neurodegenerative diseases: towards new therapeutics (Mitotarget)
Date du début: 1 févr. 2009, Date de fin: 31 mars 2012,
Mitochondrial dysfunction is a major hallmark of various neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases or Amyotrophic Lateral Sclerosis (ALS). However linking mitochondrial dysfunction to the pathogenesis of some of these diseases still needs to be elucidated. Furthermore, in pathologies where this link is already established, the question re ...
Voir le projet
19
Participants partenaires
TERMINÉ
Adipokines as Drug Targets to Combat Adverse Effects of Excess Adipose Tissue (ADAPT)
Date du début: 1 févr. 2008, Date de fin: 31 janv. 2012,
"Obesity represents the major risk factor for the cardiometabolic syndrome, which is an epidemic disease that generates a severe global socio-economic burden for the public health systems. Enhanced production of proinflammatory adipocytokines by expanded adipose tissue is now considered as a key event in the pathogenesis of this syndrome. This process involves i) the systemic release of adipokines ...
Voir le projet
12
Participants partenaires
TERMINÉ
"Mathematical modelling of beta-catenin and ras signalling in liver and its impact on proliferation, tissue organization and formation of hepatocellular carcinomas" (CANCERSYS)
Date du début: 1 nov. 2008, Date de fin: 31 oct. 2011,
"The goal of the CANCERSYS project is to establish a multi-scale model for two major signalling pathways involved in the formation of hepatocellular carcinoma, the beta-catenin and ras signalling pathways. Integrative studies linking measurements in primary heptocytes with effects at the organ level will address the impact of these signalling networks on proliferation, tissue organization and form ...
Voir le projet